ACXP vs PRAX vs ACIU vs LPSN vs NAOV

For growth investors, NanoVibronix, Inc.

(NAOV) is the stronger pick with 12. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -20. 8%, compared to -99. 9% for NanoVibronix, Inc. (NAOV). Over 10 years, the gap is even starker: PRAX returned -20. 1% versus NAOV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NanoVibronix, Inc.

(NAOV) is the lower-risk stock at 1. 49β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 62% more volatile than NAOV relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 19% for NanoVibronix, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NanoVibronix, Inc.

(NAOV) is pulling ahead at 12. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc. grew EPS 69. 8% year-over-year, compared to -37. 3% for AC Immune S. A.. Over a 3-year CAGR, NAOV leads at 14. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Acurx Pharmaceuticals, Inc.

(ACXP) is the more profitable company, earning 0. 0% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACXP leads at 0. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Praxis Precision Medicines, Inc.

(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRAX: -20. 1%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACXP (Healthcare) and PRAX (Healthcare) and ACIU (Healthcare) and LPSN (Technology) and NAOV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.